Helena Levander

Cinclus Pharma develops small molecules for the treatment of gastric acid related diseases. GERD is a digestive disorder causing retrograde flow of gastric juice into the esophagus. This leads to erosions, acid regurgitations and heartburn. Cinclus Pharma was founded by pioneers in GERD treatment, both with extensive experience from Astra and AstraZeneca, where clinical phase I and phase II studies were performed on the product candidate linaprazan. Together with the team at Cinclus Pharma the founders are now taking the development of linaprazan glurate to the next level. Cinclus Pharma’s lead drug candidate, linaprazan glurate, represents a novel class of drugs; Potassium Competitive Acid Blocker (P-CAB). A P-CAB is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. Linaprazan glurate is firstly being developed for treatment of Gastroesophageal reflux disease (GERD), clinical studies are ongoing. Linaprazan glurate has the potential to alleviate GERD symptoms and heal esophageal injuries more effectively than current pharmaceutical therapies. Cinclus Pharma is preparing for a growth journey, gathering a motivated and competent team, working closely together in realizing our strategy. Sweden is the origin of many famous global biotech innovations and successful companies. Based in Stockholm, Cinclus Pharma has a unique opportunity to level up this heritage by combining experience and contemporary science with a competent and decisive board and management. Being a clinical stage pharma company, the clinical development of linaprazan glurate is at the core of the company’s growth. Read more about the scientific progress and product development strategy at our website.

Uniflex är ett auktoriserat bemanningsföretag som arbetar med uthyrning, rekrytering och omställning av personal inom industri, lager, bygg, anläggning, städ, el och tele, reception, kundservice, försäljning och administration. Vi finns idag i Sverige, Norge och Finland och är kvalitets-, miljö- och arbetsmiljöcertifierade. Uniflex ingår i Pooliakoncernen. Uniflex är medlem i Almega Kompetensföretagen och har kollektivavtal med LO, Unionen och Akademikerförbundet. Som anställd hos Uniflex knyter du värdefulla kontakter och får bred erfarenhet av arbetslivet.

Occlutech strives to provide the best possible treatment for serious heart conditions through the development and manufacture of minimally invasive cardiac devices. Since the start of Occlutech in 2003, our products have helped thousands of patients. We are determined to continuously grow our efforts and the number of lives improved. Every beat counts.

Cinclus Pharma develops small molecules for the treatment of gastric acid related diseases. GERD is a digestive disorder causing retrograde flow of gastric juice into the esophagus. This leads to erosions, acid regurgitations and heartburn. Cinclus Pharma was founded by pioneers in GERD treatment, both with extensive experience from Astra and AstraZeneca, where clinical phase I and phase II studies were performed on the product candidate linaprazan. Together with the team at Cinclus Pharma the founders are now taking the development of linaprazan glurate to the next level. Cinclus Pharma’s lead drug candidate, linaprazan glurate, represents a novel class of drugs; Potassium Competitive Acid Blocker (P-CAB). A P-CAB is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. Linaprazan glurate is firstly being developed for treatment of Gastroesophageal reflux disease (GERD), clinical studies are ongoing. Linaprazan glurate has the potential to alleviate GERD symptoms and heal esophageal injuries more effectively than current pharmaceutical therapies. Cinclus Pharma is preparing for a growth journey, gathering a motivated and competent team, working closely together in realizing our strategy. Sweden is the origin of many famous global biotech innovations and successful companies. Based in Stockholm, Cinclus Pharma has a unique opportunity to level up this heritage by combining experience and contemporary science with a competent and decisive board and management. Being a clinical stage pharma company, the clinical development of linaprazan glurate is at the core of the company’s growth. Read more about the scientific progress and product development strategy at our website.

Lannebo Fonder is an independent and customer-oriented fund manager, focusing on active fund management within fund catagories where the company possesses unique competence. The founder of Lannebo Fonder is Anders Lannebo. He is one of Sweden's most famous and experienced fund managers, usually known as "Mr Fund"​. During 17 years, he built up Sweden's largest fund company, Robur, to the leading market position it has today. Our fund managers are regarded as the absolute top in their categories and every one of them have worked more than 7 years in the financial sector.

Rejlers is one of the leading engineering consultancy firms in the Nordic region. With cutting-edge expertise, we help companies, public authorities and other organisations meet tomorrow's societal challenges. Our services are important building blocks for achieving a sustainable society. Founded in 1942, Rejlers success is built on the ability to constantly embrace new knowledge. Our vision "Home of the learning minds" guides us to continuous learning, development and growth. With operations in Sweden, Finland, Norway and the United Arab Emirates, Rejlers has over 3300 experts in technology areas such as energy, industry, infrastructure and real estate. In 2022, the company had a turnover of 3.5 billion SEK and its class B share is listed on Mid Cap, Nasdaq Stockholm.

Stendörren äger, utvecklar och förvaltar lokaler som gör skillnad. Det betyder att vi arbetar tillsammans med våra hyresgäster för att tillhandahålla ändamålsenliga lokaler med konkurrenskraftiga hyror, främst i Storstockholm och Mälardalen i bland annat Högdalen, Veddesta, Upplands-Bro, Enköping, Västerås, Flen och Eskilstuna. Vi driver även projektutveckling av tidigare utnyttjad tomtmark i samma områden.